In exercise of the powers conferred by paragraphs 4 5 6 10 11 14 15 16 17 and 18

REGD. NO. D. L.-33004/99 EXTRAORDINARY II— — (ii) PART II—Section 3—Sub-section (ii) PUBLISHED BY AUTHORITY 1494] No. 1494] NEW DELHI, WEDNESDAY, MAY 24, 2017/JYAISTHA 3, 1939 jlk;u vkSj moZjd ea=ky; ¼vkS"k/k foHkkx½ ¼jk"Vªh; vkS"k/k eYw ; fu/kkZj.k izkf/kdj.k½ vkn”s k ubZ fnYyh] 24 ebZ] 2017 dk-vk- 1687¼v½-&Hkkjr ljdkj ds jlk;u vkSj moZjd e=a ky; }kjk tkjh dk-vk- 1394¼v½ rkjh[k 30 ebZ] 2013 vkSj dk-vk- 701¼v½ rkjh[k 10 ekpZ] 2016 ds lkFk ifBr vkS"k/k ¼dher fu;a=.k½ vkns'k] 2013 ds iSjk 4] 5] 6] 10] 11] 14] 15] 16] 17 vkSj 18 }kjk iznRr 'kfDr;ks a dk iz;ksx djr s gq,] jk’Vªh; vkS’k/k eYw ; fu/kkZj.k izkf/kdj.k ¼ftls laf{kIr :i ls ,uihih, dgk tkrk gS½ uhps dh lkj.kh ds LraHk ¼5½ eas fofufnZ’V vf/kdre dher dk s mDr lkj.kh ds LraHk ¼3½ vkSj ¼4½ eas Øe“k% rRLFkkuh izfof’V;ks a eas fofufnZ’V [kqjkd :i ,oa izcyrk vkSj bdkbZ lfgr ml lkj.kh ds LraHk ¼2½ eas dh rRLFkkuh izfof’V es a fofufnZ’V vulq wfpr fofufeZfr;ks a eas ls izR;sd dh] LFkkuh; dj] ;fn dksbZ gS] dks NksM+dj vf/kdre dher ds :i es a fu;r djrh gS% lkj.kh dz-la- vuqlwfpr fofufeZfr dk uke [kqjkd :i ,oa izcyrk bdkbZ vf/kdre dher ¼#-½ (1) (2) (3) (4) ¼5½ 1. eksjQhu batsD“ku 15 fexzk-@fefy- 1 fefy- 28.04 2. lksfM;e oSyijks,V lhvkj xksyh 500 fexzk- 1 xksyh 8.82 3. lksfM;e oSyijks,V lhvkj xksyh 300 fexzk- 1 xksyh 5.73 4. dks,xqys“ku QSDVj VIII batsD“ku ds fy, ikmMj 500 vkbZ;w izfr iSd 8,316.70 5. LihjksuksySDVksu xksyh 50 fexzk- 1 xksyh 3.60 6. fMDyksQsud dSIlwy 50 fexzk- 1 dSIlwy 0.58 7. bcqizksQsu dSIlwy 400 fexzk- 1 dSIlwy 1.00 8. DyksVªhektksy Ykks“ku 1% 1 fefy- 3.39 9. ijesFkfju Øhe 1% 1 xzke 1.52 10. ijesFkfju tSy 5% 1 xzke 1.38 11. ijesFkfju Ykks“ku 5% 1 fefy- 0.92 12. DyksfeQhu dSIlwy 50 fexzk- 1 dSIlwy 28.97 13. isjkflVkeksy batsD“ku 150 fexzk-@fefy- izfr iSd 2.90 3349 GI/2017 (1)2 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] ¼0-5 fefy-½ 14. isjkflVkeksy batsD“ku 150 fexzk-@fefy- izfr iSd 3.97 ¼1 fefy-½ 15. isjkflVkeksy batsD“ku 150 fexzk-@fefy- izfr iSd 8.24 ¼3 fefy-½ 16. isjkflVkeksy batsD“ku 150 fexzk-@fefy- izfr iSd 10.37 ¼4 fefy-½ 17. isjkflVkeksy batsD“ku 150 fexzk-@fefy- izfr iSd 12.51 ¼5 fefy-½ 18. isjkflVkeksy batsD“ku 150 fexzk-@fefy- izfr iSd 16.78 ¼7 fefy- ½ 19. MhihVh$fgc$gsi ch oSDlhu 0-1 fefy- 72.874 uksV % ¼d½ ljdkj }kjk bl izdkj fu;r dh xbZ vkSj vf/klwfpr dh xbZ vf/kdre dher ¼/ku LFkkuh; dj] tk s ykxw gks½a ls vf/kd dher ij vuqlwfpr fofufeZfr;ks a ds czkaMsM ;k tsufsjd ;k nksuks a :ikarjks a dks csp jgs vuqlwfpr fofufeZfr;ks a ds lHkh fofuekZrk] mi;qZDr lkj.kh ds LraHk ¼5½ e as of.kZr vf/kdre dher ¼/ku LFkkuh; dj] tk s ykxw gks½a ls vf/kd lHkh ,slh fofufeZr;ks a dh dher dk v/kkseq[kh iqujh{k.k djasxsA ¼[k½ lHkh ekStwnk fuekZrkvks a dks mi;qZDr dfFkr vuqlwfpr fofufeZfr;ks a ds vf/kdre [kqnjk dher mi;qZDr lkj.kh ds LraHk ¼5½ eas fofufnZ"V vf/kdre dher LFkkuh; dj lfgr ls de gS rks] tgka dgh Hkh ykxw gks] vkS"k/k ¼eYw ; fu;a=.k½ vkn's k] 2013 ds iSjkxzkQ 13¼2½ ds vuqlkj mldks ekStwnk vf/kdre [kqnjk dher dks cuk, j[kuk gksxkA ¼x½ vxj fuekZrkvks a u s mi;qZDr lkj.kh ds LraHk ¼5½ eas of.kZr vf/kdre dher ij ljdkj dks okLro es a Hkqxrku fd;k gS ;k ;g n;s gS rks os LFkkuh; djks a dks tksM+ ldr s gSaA ¼?k½ vkS"k/k ¼ewY; fu;a=.k½ vkn's k] 2013 ds iSjkxzkQ 11 es a fn, x, izko/kkuks a ds rgr lEcfU/kr fuekZrkvks a dk s mi;qZDr lkj.kh ds LraHk ¼5½ eas fofufnZ"V vf/kdre dher ds vk/kkj ij vuqlwfpr fofufeZfr;ks a ds iSdkas ds fy, vf/kdre dher fu/kkZfjr djasA fuekZrk vkS"k/k ¼ewY; fu;a=.k½ vkn's k] 2013 ds iSjkxzkQ 24 ds rgr QkWeZ&V eas vf/klwpuk dh rkjh[k ls vkbZihMh,e,l ds ek/;e ls Hkjdj ,uihih, dk s ,d ewY; lwph tkjh djs a rFkk mldh dkWih jkT; vkS”kf/k fu;a=dks a vkSj fofuekZrk forjdks a dks tkjh djsAa ¼M+½ vkS"k/k ¼ewY; fu;a=.k½ vkn's k] 2013 ds 24 ¼4½ ds mica/kks a ds vuqlkj izR;sd QqVdj fodzsrk vkSj forjd fofuekZrk }kjk fn, x, :i eas ,sl s ifjlj] tgka dkjksckj dks bl izdkj fd;k tk jgk gS fd mlls ijke“kZ ds bPNqd fdlh O;fDr ds fy, igqap vklku gks] ogka mlds fdlh lgtn`’; Hkkx ij dher lwph vkSj iwjd lwph] ;fn dksbZ gks] dks laiznf”kZr djsxkA ¼p½ mi;qZDr lkj.kh ds LraHk ¼5½ eas fofufnZ"V vf/kdre dher ds fy, fofufnZ"V vulq wfpr fofufeZfr;ks a ds fofufnZ"V fofHkUu rjhds vkSj izcyrk ls fHkUu vxj ekStwnk fuekZrkvks a }kjk ,d ubZ vkS"kf/k dks ykap djrk gS rks ml s igy s vkS"k/k ¼ewY; fu;a=.k½ vkn's k] 2013 ds iSjkxzkQ 2¼;w½ ds vuqlkj vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds rgr lwph II eas fofufnZ"V QkeZ I ds ek/;e ls ,uihih, eas ewY; fu/kkZj.k gsrq vkosnu djuk gksxkA ¼N½ mi;qZDr vulq wfpr fofufeZfr;ks a dh mRiknu@vk;kr vkSj fcØh ds lEcU/k eas fuekZrkvksa dks vkS"k/k ¼ewY; fu;a=.k½ vkn's k] 2013 ds lwph II ds QkWeZ III dks vkbZihMh,e,l ds ek/;e ls Hkjdj ,uihih, dks gj frekgh dh fjiksVZ izLrqr djsxkA mi;qZDr vuqlwfpr fofufeZfr;ks a ds fuekZ.k dks dksbZ fuekZrk mRiknu cUn djus dk bPNqd gks rks bldh lwpuk ,uihih, dks voxr djk;sxkA blds lEcU/k eas vxj vuqlwfpr fofufeZfr;ks a ds mRiknu vkSj vk;kr dk s cUn dju s dk bPNqd gS rks cUn dju s dh frfFk ls N% eghus igys lwph II ds QkWeZ IV eas Hkjdj ,uihih, dks izLrqr djsxkA ¼Tk½ fofuekZrk ;k foi.ku dEiuh] mijksDr dfFkr lkj.kh eas n'kkZ;s vf/kdre ewY; vkSj 'krks± dk ikyu ugha djrh gSa rks os vko';d oLrq,¡ vf/kfu;e] 1955 ds lkFk ifBr Mhihlhvks] 2013 ds izko/kkuks a ds v/khu C;kt lfgr vf/kizHkkfjr jkf'k dks tek dju s ds fy, nk;h gksxa sA ¼>½ bl vkns'k eas mijksDr lkj.kh ds LraHk ¼2½ eas dh rRLFkkuh izfof"V es a fofufnZ"V ,slh fofufeZfr;ks a ds iSdkas dh vf/kdre dher fu;r gksus ds ifj.kkeLo#i] vf/kdre ;k [kqnjk ewY; fu/kkZfjr vkns'k ;fn dksbZ gks] tks fd bl vkn's k ls iwoZ tkjh gq, gS] Lor% gh vf/kØe.k gks tk;sxa sA [dk-ala-@177@45@2017@,Q@ Qk- la- 8¼45½@2017@Mhih@,uihih,&fMoh-II] cythr flag] lgk;d funs'kdII (ii) 3 MINISTRY OF CHEMICALS AND FERTILIZERS (Department of Pharmaceuticals) (NATIONAL PHARMACEUTICAL PRICING AUTHORITY) ORDER New Delhi, the 24th May, 2017 S.O. 1687(E).—In exercise of the powers conferred by paragraphs 4, 5, 6, 10, 11, 14, 15, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the prices as specified in column (5) of the table herein below as ceiling price exclusive of local tax applicable, if any, in respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof: TABLE Sl. No. Name of the Scheduled Dosage form & Strength Unit Ceiling Price Formulation (Rs.) (1) (2) (3) (4) (5) 1. Morphine Injection 15mg/ml 1 ML 28.04 2. Sodium Valproate CR Tablet 500 mg 1 Tablet 8.82 3. Sodium Valproate CR Tablet 300 mg 1 Tablet 5.73 4. Coagulation factor VIII Powder for Injection 500 IU Each Pack 8,316.70 5. Spironolactone Tablet 50 mg 1 Tablet 3.60 6. Diclofenac Capsule 50mg 1 Capsule 0.58 7. Ibuprofen Capsule 400mg 1 Capsule 1.00 8. Clotrimazole Lotion 1% 1 ML 3.39 9. Permethrin Cream 1% 1 GM 1.52 10. Permethrin Gel 5% 1 GM 1.38 11. Permethrin Lotion 5% 1 ML 0.92 12. Clomiphene Capsule 50mg 1 Capsule 28.97 13. Paracetamol Injection 150mg/ml Each Pack 2.90 (0.5 ML) 14. Paracetamol Injection 150mg/ml Each Pack 3.97 (1 ML) 15. Paracetamol Injection 150mg/ml Each Pack 8.24 (3 ML) 16. Paracetamol Injection 150mg/ml Each Pack 10.37 (4 ML) 17. Paracetamol Injection 150mg/ml Each Pack 12.51 (5 ML) 18. Paracetamol Injection 150mg/ml Each Pack 16.78 (7 ML) 19. DPT + Hib + Hep B Vaccine 0.1 ML 72.874 Note: (a) All manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus local taxes as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus local taxes as applicable, if any. (b) All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus local taxes as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013. (c) The manufacturers may add local taxes only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table. (d) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.4 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] (e) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same. (f) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013. (g) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. (h) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955. (i) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded. [PN/177/45/2017/F/F. No. 8(45)/2017/D.P./NPPA-Div.-II BALJIT SINGH, Assistant Director vkn”s k ubZ fnYyh] 24 ebZ] 2017 dk-vk- 1688¼v½-& Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky; }kjk tkjh dk-vk- 1394¼v½ rkjh[k 30 ebZ] 2013 vkSj dk- vk- 701¼v½ rkjh[k 10 ekpZ] 2016 ds lkFk ifBr vkS"k/k ¼dher fu;a=.k½ vkn's k] 2013 ds iSjk 4] 6] 10] 11] 14] 16] 17 vkSj 18 }kjk iznRr 'kfDr;ks a dk iz;ksx djr s gq, vkSj Hkkjr ljdkj es a jlk;u ,oa moZjd e=a ky; ¼jk"Vªh; vkS"k/k eYw ; fu/kkZj.k izkf/kdj.k½ ds dk- vk- 1040¼v½ fnukad 01 vizSy] 2017 vkSj dk- vk- 1090¼v½ fnukad 06 vizSy] 2017 ds vkns“k ds vf/kdze.k es a tgka rd mldk laca/k uhps dh lkj.kh ds fofufeZfr iSd ls gS] mu ckrks a ds flok; vf/kØkUr djrs gq, ftUgs a ,sl s vf/kØe.k ds iwoZ fd;k x;k gS ;k dju s dk yksi fd;k x;k gS] jk"Vªh; vkS"k/k eYw ; fu/kkZj.k izkf/kdj.k uhps dh lkj.kh ds LraHk ¼5½ eas fofufnZ"V vf/kdre dher dks mDr lkj.kh ds LraHk ¼3½ vkSj ¼4½ eas Øe“k% rRLFkkuh izfof"V;ks a eas fofufnZ"V [kqjkd :i ,oa izcyrk vkSj bdkbZ lfgr ml lkj.kh ds LraHk ¼2½ eas dh rRLFkkuh izfof"V eas fofufnZ"V vuqlwfpr fofufeZfr;ks a eas ls izR;sd dh] LFkkuh; dj] ;fn dksbZ gS] dk s NksM+dj vf/kdre dher ds :i eas fu;r djrh gS% lkj.kh dz-la- vuqlwfpr fofufeZfr dk uke [kqjkd :i ,oa izcyrk bdkbZ vf/kdre dher ¼#-½ (1) (2) (3) (4) (5) 1. eksjQhu batsD“ku 10 fexzk-@fefy- 1 fefy- 22-47 2. eksjQhu Xkksyh 10 fexzk- 1 xksyh 5-04 3. Xywdkst batsD“ku 10% izfr iSd 26-58 ¼500 fefy-½ 4. Xywdkst batsD“ku 10% izfr iSd 24-43 ¼1000 fefy-½ 5. MhihVh oSDlhu 0-5 fefy- 12-85 6. gsisVkbZfVl ch oSDlhu 1 fefy- 71-06 7. Lusd osukse ,UVhlsje 10 fefy- 527-21 ykbQksykbM iksyhoysUV iSd 8. gsikfju batsD“ku 5000 vkbZ;w@fefy- 1 fefy- 36-73 9. vkbZ;wMh dkWij lfgr Ykblsla ds vuqlkj 1 vkbZ;wMh 260-87 10. fjQefiflu Xkksyh 150 fexzk- 1 xksyh 1-53 11. ¶ydw ksuktkys dSIlwy 150 fexzk- 1 dSIlwy 17-55 uksV % ¼d½ ljdkj }kjk bl izdkj fu;r dh xbZ vkSj vf/klwfpr dh xbZ vf/kdre dher ¼/ku LFkkuh; dj] tks ykxw gks½a ls vf/kd dher ij vuqlwfpr fofufeZfr;ks a ds czkaMsM ;k tsufsjd ;k nksuks a :ikarjks a dks csp jgs vuqlwfpr fofufeZfr;ks a ds lHkh fofuekZrk]II (ii) 5 mi;qZDr lkj.kh ds LraHk ¼5½ eas of.kZr vf/kdre dher ¼/ku LFkkuh; dj] tk s ykxw gks½a ls vf/kd lHkh ,slh fofufeZr;ks a dh dher dk v/kkseq[kh iqujh{k.k djasxsA ¼[k½ lHkh ekStwnk fuekZrkvks a dks mi;qZDr dfFkr vuqlwfpr fofufeZfr;ks a ds vf/kdre [kqnjk dher mi;qZDr lkj.kh ds LraHk ¼5½ eas fofufnZ"V vf/kdre dher LFkkuh; dj lfgr ls de gS rks] tgka dgh Hkh ykxw gks] vkS"k/k ¼eYw ; fu;a=.k½ vkn's k] 2013 ds iSjkxzkQ 13¼2½ ds vuqlkj mldks ekStwnk vf/kdre [kqnjk dher dks cuk, j[kuk gksxkA ¼x½ vxj fuekZrkvks a u s mi;qZDr lkj.kh ds LraHk ¼5½ eas of.kZr vf/kdre dher ij ljdkj dks okLro es a Hkqxrku fd;k gS ;k ;g n;s gS rks os LFkkuh; djks a dks tksM+ ldr s gSaA ¼?k½ vkS"k/k ¼ewY; fu;a=.k½ vkn's k] 2013 ds iSjkxzkQ 11 es a fn, x, izko/kkuks a ds rgr lEcfU/kr fuekZrkvks a dk s mi;qZDr lkj.kh ds LraHk ¼5½ eas fofufnZ"V vf/kdre dher ds vk/kkj ij vuqlwfpr fofufeZfr;ks a ds iSdkas ds fy, vf/kdre dher fu/kkZfjr djasA fuekZrk vkS"k/k ¼eYw ; fu;a=.k½ vkn's k] 2013 ds iSjkxzkQ 24 ds rgr QkWeZ&V eas vf/klwpuk dh rkjh[k ls vkbZihMh,e,l ds ek/;e ls Hkjdj ,uihih, dk s ,d eYw ; lwph tkjh djs a rFkk mldh dkWih jkT; vkS’kf/k fu;a=dks a vkSj fofuekZrk forjdkas dk s tkjh djsAa ¼M+½ vkS"k/k ¼ewY; fu;a=.k½ vkn's k] 2013 ds 24 ¼4½ ds mica/kks a ds vuqlkj izR;sd QqVdj fodzsrk vkSj forjd fofuekZrk }kjk fn, x, :i eas ,sl s ifjlj] tgka dkjksckj dks bl izdkj fd;k tk jgk gS fd mlls ijke“kZ ds bPNqd fdlh O;fDr ds fy, igqap vklku gks] ogka mlds fdlh lgtn`”; Hkkx ij dher lwph vkSj iwjd lwph] ;fn dksbZ gks] dks laiznf”kZr djsxkA ¼p½ mi;qZDr lkj.kh ds LraHk ¼5½ eas fofufnZ"V vf/kdre dher ds fy, fofufnZ"V vulq wfpr fofufeZfr;ks a ds fofufnZ"V fofHkUu rjhds vkSj izcyrk ls fHkUu vxj ekStwnk fuekZrkvks a }kjk ,d ubZ vkS"kf/k dks ykap djrk gS rks ml s igy s vkS"k/k ¼ewY; fu;a=.k½ vkn's k] 2013 ds iSjkxzkQ 2¼;w½ ds vuqlkj vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds rgr lwph II eas fofufnZ"V QkeZ I ds ek/;e ls ,uihih, eas ewY; fu/kkZj.k gsrq vkosnu djuk gksxkA ¼N½ mi;qZDr vulq wfpr fofufeZfr;ks a dh mRiknu@vk;kr vkSj fcØh ds lEcU/k eas fuekZrkvksa dks vkS"k/k ¼ewY; fu;a=.k½ vkn's k] 2013 ds lwph II ds QkWeZ III dks vkbZihMh,e,l ds ek/;e ls Hkjdj ,uihih, dks gj frekgh dh fjiksVZ izLrqr djsxkA mi;qZDr vuqlwfpr fofufeZfr;ks a ds fuekZ.k dks dksbZ fuekZrk mRiknu cUn djus dk bPNqd gks rks bldh lwpuk ,uihih, dks voxr djk;sxkA blds lEcU/k eas vxj vuqlwfpr fofufeZfr;ks a ds mRiknu vkSj vk;kr dk s cUn dju s dk bPNqd gS rks cUn dju s dh frfFk ls N% eghus igys lwph II ds QkWeZ IV es a Hkjdj ,uihih, dks izLrqr djsxkA ¼Tk½ fofuekZrk ;k foi.ku dEiuh] mijksDr dfFkr lkj.kh eas n'kkZ;s vf/kdre ewY; vkSj 'krks± dk ikyu ugha djrh gSa rks os vko';d oLrq,¡ vf/kfu;e] 1955 ds lkFk ifBr Mhihlhvks] 2013 ds izko/kkuks a ds v/khu C;kt lfgr vf/kizHkkfjr jkf'k dks tek dju s ds fy, nk;h gksaxsA ¼>½ bl vkns'k eas mijksDr lkj.kh ds LraHk ¼2½ eas dh rRLFkkuh izfof"V es a fofufnZ"V ,slh fofufeZfr;ks a ds iSdkas dh vf/kdre dher fu;r gksus ds ifj.kkeLo#i] vf/kdre ;k [kqnjk ewY; fu/kkZfjr vkns'k ;fn dksbZ gks] tks fd bl vkn's k ls iwoZ tkjh gq, gS] Lor% gh vf/kØe.k gks tk;sxa sA [dk-ala-@177@45@2017@,Q@ Qk- la- 8¼45½@2017@Mhih@,uihih,&fMoh-II] cythr flag] lgk;d funs'kd ORDER New Delhi, the 24th May, 2017 S.O. 1688 (E).—In exercise of the powers conferred by paragraphs 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) No. S.O. 1040(E) dated 1st April, 2017 and S.O. 1090(E) dated 6th April, 2017 in so far as it relates to formulation packs mentioned in the table below, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby fixes the price as specified in column (5) of the table herein below as ceiling price exclusive of local tax applicable, if any in respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage from & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:6 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] TABLE Sl. No. Name of the Scheduled Dosage form & Strength Unit Ceiling Formulation Price (Rs.) (1) (2) (3) (4) (5) 1. Morphine Injection 10mg/ml 1 ML 22.47 2. Morphine Tablet 10mg 1 Tablet 5.04 3. Glucose Injection 10% Each Pack 26.58 (500 ML) 4. Glucose Injection 10% Each Pack 24.43 (1000 ML) 5. DPT Vaccine 0.5 ML 12.85 6. Hepatitis B Vaccine 1 ML 71.06 7. Snake venom antiserum - 10 ML Pack 527.21 Lyophilized polyvalent 8. Heparin Injection 5000 IU/ml 1 ML 36.73 9. IUD containing Copper As Licensed 1 IUD 260.87 10. Rifampicin Tablet 150mg 1 Tablet 1.53 11. Fluconazole Capsule 150mg 1 Capsule 17.55 Note: (a) All manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus local taxes as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus local taxes as applicable, if any. (b) All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus local taxes as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013. (c) The manufacturers may add local taxes only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table. (d) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers. (e) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same. (f) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013. (g) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. (h) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955. (i) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded. [PN/177/45/2017/F /F. No. 8(45)/2017/D.P./NPPA-Div.-II] BALJIT SINGH, Assistant DirectorII (ii) 7 vkn”s k ubZ fnYyh] 24 ebZ] 2017 dk-vk- 1689¼v½-&Hkkjr ljdkj ds jlk;u vkSj moZjd e=a ky; }kjk tkjh dk-vk- 1394¼v½ rkjh[k 30 ebZ] 2013 vkSj dk0 vk0 701¼v½ rkjh[k 10 ekpZ] 2016 ds lkFk ifBr vkS"k/k ¼dher fu;a=.k½ vkn's k] 2013 ds iSjk 5] 11 vkSj 15 }kjk iznRr 'kfDr;ks a dk iz;ksx djr s gq,] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k ¼ftldks laf{kIr :i eas ,uihih, dgk tkrk gS½] uhps dh lkj.kh ds LraHk ¼6½ esa fofufnZ"V [kqnjk ewY; dks mDr lkj.kh ds LraHk ¼3½] ¼4½] vkSj ¼5½ esa Øe'k% rRLFkkuh izfof"V;ks a es a fofufnZ"V izcyrk] bdkbZ ¼;wfuV½ vkSj fofuekZrk vkSj foi.ku dEifu;ks a ds uke lfgr Øe'k% LraHk ¼2½ es a dh rRLFkkuh izfof"V es a ls izR;sd dh] LFkkuh; dj] ;fn dksbZ gS] dks NksM+dj vf/kdre [kqnjk ewY; ds :i es a fu;r djrh gSA lkj.kh Ø- vuqlwfpr fofufeZfr izcyrk bdkbZ fofuekZrk vkSj foi.ku [kqnjk eYw ; la- dk uke@czkaM dk uke daiuh dze’k% ¼#-½ (1) (2) (3) (4) (5) (6) 1. Vys felkVZu$ izR;sd fQYe fyfir ck;y;s MZ xksyh 1 xksyh eSllZ I;ksj ,aM D;wj 7.95 eVs ksizksyksy bZvkj xksyh eas: Vys felkVZu 40 fexzk- esVksizksyksy gsYFkds;j izk- fy- ¼Vys fetwc csVk 25½ lqLlhusV ds cjkcj esVksizksyksy @eSllZ twfcyasV VkjVªVs 25 fexzk- ¼,DlVsfaMM fjyht ykbQ lkbaflt fy- eas½ 2. Vys felkVZu$ izR;sd fQYe fyfir ck;y;s MZ xksyh 1 xksyh eSllZ I;ksj ,aM D;wj 9.55 eVs ksizksyksy bZvkj xksyh eas: Vys felkVZu 40 fexzk- esVksizksyksy gsYFkds;j izk- fy- ¼Vys fetwc csVk 50½ lqLlhusV ds cjkcj esVksizksyksy @eSllZ twfcyasV VkjVªVs 50 fexzk- ¼,DlVsfaMM fjyht ykbQ lkbaflt fy- eas½ 3. XyhehfijkbM$ izR;sd vfyfir ck;y;s MZ xksyh eas% 10 eSllZ foaMykl 71.43 oksXyhckWl esVQksfeZu XyhehfijkbM 1 fexzk- oksXyhckWl 0-2 xksfy;ka ck;ksVsd fy-@eSllZ ,lvkj xksyh fexzk- esVQksfeZu ,plh,y 500 fexzk- XysuekdZ ¼llVUs M fjyht QkWeZ eas½ QkekZL;wfVdYl fy- 4. XyhehfijkbM$ izR;sd vfyfir ck;y;s MZ xksyh eas% 10 eSllZ foaMykl 90.48 oksXyhckWl esVQksfeZu XyhehfijkbM 2 fexzk- oksXyhckWl 0-2 xksfy;ka ck;ksVsd fy-@eSllZ ,lvkj xksyh fexzk- esVQksfeZu ,plh,y 500 fexzk- XysuekdZ ¼llVUs M fjyht QkWeZ eas½ QkekZL;wfVdYl fy- 5. Vys felkVZu$ izR;sd vfyfir ck;y;s MZ xksyh eas% 1 xksyh eSllZ foaMykl 7.00 DyksjFkkfyMu xksyh Vys felkVZu 80 fexzk- DyksjFkkfyMu ck;ksVsd fy-@eSllZ ¼Vys izsl lhVh 80½ 12-5 fexzk- ,CcksV gsYFkds;j izk- fy- 6. fMDyksQsud izR;sd xzke eas% fMDyksQsud 1 xzke eSllZ nh enzkl 2.32 MkbfFkykekbu$ MkbfFkykekbu 1-16% MCY;w@MCY;w QkekZL;wfVdYl@ fyulhM ¼fMDYkksQsud lksfM;e 1% eSllZ Cyw Øksl ySc- vkW;y$feFkkby MCY;w@MCY;w ds 1cjkcj½ fyulhM izk- fy- lsyhlkbysV$ vkW;y 3% MCY;w@MCY;w eus Fkksy tSy eFs khylsyhlkbysV 10% MCY;w@MCY;w ¼fMDyksVsy$tSy½ eus Fkksy 5% MCY;w@MCY;w 7. jkstqIysV 10 dSIlwy izR;sd gkMZ tsykVkbu dSIlwy eas% 1 dSIlwy eSllZ VkWjsVa 13.94 jkslqoklVsfVu dSfY’k;e ds cjkcj QkekZL;wfVdYl fy-@ jkslqoklVsfVu 10 fexzk- ¼iSyVs l eas½ eSllZ lk;uksdse DyksfiMksxzsy ckbZlYQsV ds cjkcj QkekZL;wfVdYl DyksfiMksxzsy 75 fexzk- ¼iSyVs l eas½ uksV % ¼d½ mi;qZDr nh xbZ fofufnZ"V QkWewZys'ku ds fofuekZrk vFkkZr tks ÞubZ Mªxß Mhihlhvks] 2013 ds iSjkxzkQ 2¼;w½ ds rgr mi;qZDr nh xbZ lkj.kh ds LrHa k ¼6½ es a fofufnZ"V [kqnjk eYw ; fu/kkZfjr djsxa sA8 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] ¼[k½ vxj fuekZrkvks a u s mi;qZDr lkj.kh ds LraHk ¼6½ eas of.kZr vf/kdre dher ij ljdkj dks okLro eas Hkqxrku fd;k gS ;k ;g n;s gS rks os LFkkuh; djks a dks tksM+ ldr s gSaA ¼x½ vkS"k/k ¼ewY; fu;a=.k½ vkn's k] 2013 ds iSjkxzkQ 11 eas fn, x, izko/kkuks a ds rgr fuekZrkvks a dks mi;qZDr lkj.kh ds LrHa k ¼6½ eas fofufnZ"V [kqnjk eYw ; ds vk/kkj ij vuqlwfpr fofufeZfr;ks a ds iSdks a ds fy, [kqnjk eYw ; fu/kkZfjr djsAa fuekZrk vkS"k/k ¼ewY; fu;a=.k½ vkn's k] 2013 ds iSjkxzkQ 24 ds rgr QkWeZ V eas vf/klwpuk dh rkjh[k ls ,d eYw ; lwph ,uihih, dks vkbZihMh,e,l ds ek/;e ls tkjh djsAa ¼?k½ vkS"k/k ¼ewY; fu;a=.k½ vkn's k] 2013 ds 24 ¼4½ ds mica/kks a ds vuqlkj izR;sd QqVdj fodzsrk vkSj forjd fofuekZrk }kjk fn, x, :i es a ,sl s ifjlj] tgka dkjckj dk s bl izdkj fd;k tk jgk gS fd mlls ijke’kZ ds bPNqd fdlh O;fDr ds fy, igqap vklku gks] ogka mlds fdlh lgtn`”; Hkkx ij dher lwph vkSj iwjd lwph] ;fn dksbZ gks] dks laiznf”kZr djsxkA ¼M-½ mi;qZDr xSj vf/kdre dher ¼[kqnjk ewY;½ dsoy mi;qZDr fuekZrk@foi.ku ds fy, ykxw gS tSlk fd mUgksua s vkS"k/k ¼ewY; fu;a=.k½ vkn's k] 2013 ds rgr vuqc) ewY; fu/kkZj.k@la'kks/ku ds fy, QkWeZ I ij tek fd;k x;k Fkk vkSj ljdkj }kjk fu/kkZfjr lHkh ykxw oS/kkfud vko';drkvks a dh iwfrZ ds v/khu izklafxd fof/k;ks@a fu;eksa ds vUrxZr tSlk fd dsUnzh;@jkT; ykblsflax vkWFkksfjVh ds l{ke izkf/kdkjh }kjk esU;wQsDpfjxa ykblsla eta wjh ds rgr lacaf/kr fofufeZr fuekZrk@foi.ku dEifu;ka tks vuqikyu djrh gSA ¼p½ mi;qZDr fofufeZfr;ks a dh mRiknu@vk;kr vkSj fcØh ds lEcU/k eas lEcfU/kr fuekZrkvks a dks vkS"k/k ¼ewY; fu;a=.k½ vkn's k] 2013 ds vuqlwph II ds QkWeZ III dks vkbZihMh,e,l ds ek/;e ls Hkjdj ,uihih, dks gj frekgh dh fjikVs Z izLrqr djsxkA mi;qZDr fofufeZfr;ks a ds fuekZ.k dk s dkbs Z fuekZrk mRiknu cUn dju s dk bPNqd gks rks bldh lwpuk ,uihih, dks voxr djk;sxkA blds lEcU/k eas vxj fofufeZfr;ks a ds mRiknu vkSj vk;kr dk s cUn djus dk bPNqd gS rks cUn dju s dh frfFk ls N% eghus igy s lwph II ds QkWeZ IV eas Hkjdj ,uihih, dks izLrqr djxs kA ¼N½ fofuekZrk ;k foi.ku dEiuh] mijksDr fofufeZfr;ks a vkSj fofufnZ"V 'krks± dk ikyu ugh a djrh gSa rks os vko';d oLrq,¡ vf/kfu;e] 1955 ds lkFk ifBr Mhihlhvks] 2013 ds izko/kkuks a ds v/khu C;kt lfgr vf/kizHkkfjr jkf'k dks tek dju s ds fy, nk;h gksxa sA ¼t½ bl vkn's k eas mijksDr lkj.kh ds LraHk ¼2½ eas dh rRLFkkuh izfof"V eas fofufnZ"V fofufeZfr;ks a ds iSdks a dk [kqnjk eYw ; fu;r gksus ds ifj.kkeLo#i ,sl s vkn's k tks fd bl vkn's k ls iwoZ tkjh gq, gS] Lor% gh fujLr gks tk;sxa sA [dk-ala-@177@45@2017@,Q@ Qk- la- 8¼45½@2017@Mhih@,uihih,&fMoh-II] cythr flag] lgk;d funs'kd ORDER New Delhi, the 24th May, 2017 S.O. 1689 (E).—In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of local taxes, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company respectively, as specified in the corresponding entries in columns (3), (4) and (5) thereof; TABLE Sl. Name of the Strength Unit Manufacturer & Retail No. Scheduled Marketing Company Price (Rs.) Formulation / Brand respectively Name (1) (2) (3) (4) (5) (6) 1. Telmisartan + Each film coated bilayered 1 M/s Pure and Cure 7.95 Metoprolol ER Tablet tablet contains: Tablet Healthcare Pvt. Ltd./ M/s (Telmijub Beta 25) Telmisartan 40mg Jubilant Life Sciences Metoprolol succinate eq. to Limited Metoprolol Tartrate 25mg (as extended release)II (ii) 9 2. Telmisartan + Each film coated bilayered 1 Tablet M/s Pure and Cure 9.55 Metoprolol ER Tablet tablet contains: Healthcare Pvt. Ltd./ M/s (Telmijub Beta 50) Telmisartan 40mg Jubilant Life Sciences Metoprolol succinate eq. to Limited Metoprolol Tartrate 50mg (as extended release) 3. Glimepiride + Each uncoated bilayered 10 M/s Windlas Biotech 71.43 Voglibose + tablet contains: Tablets Ltd./M/s Glenmark Metformin SR Tablet Glimepiride 1mg Pharmaceuticals Ltd. Voglibose 0.2mg Metformin HCL 500mg (as sustained released form) 4. Glimepiride + Each uncoated bilayered 10 M/s Windlas Biotech 90.48 Voglibose + tablet contains: Tablets Ltd./M/s Glenmark Metformin SR Tablet Glimepiride 2mg Pharmaceuticals Ltd. Voglibose 0.2mg Metformin HCL 500mg (as sustained released form) 5. Telmisartan + Each uncoated bilayered 1 Tablet M/s Windlas Biotech 7.00 Chlorthalidone tablet contains: Ltd./M/s Abbott Healthcare Tablet Telmisartan 80mg Pvt. Ltd. (Telpres CT 80) Chlorthalidone 12.5mg 6. Diclofenac Each gm contains: 1 GM M/s The Madras 2.32 Diethylamine + Diclofenac Diethylamine Pharmaceuticals /M/s Blue Linseed Oil + Methyl 1.16% w/w Cross Lab. Pvt. Ltd. Salicylate + Menthol (eq. to diclofenac Sodium Gel 1% w/w) ( DICLOTAL+ Gel) Linseed Oil 3% w/w Methyl Salicylate 10% w/w Menthol 5% w/w 7. Rozuplatt 10 Capsules Each hard gelatine capsule 1 Capsule M/s Torrent Pharmaceuticals 13.94 contains: Ltd.,/ M/s Synokem Rosuvastatin calcium eq. to Pharmaceuticals Ltd. Rosuvastatin 10mg (As pellets) Clopidogrel Bisulphate eq. to Clopidogrel 75mg (As pellets) Note: (a) The manufacturers of above mentioned formulations i.e. ―new drug‖ under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove. (b) The manufacturers may add local taxes only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table. (c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturers in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturers shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers. (d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same. (e) The above mentioned retail price is applicable only to the individual manufacturers/marketeers as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation/revision as stipulated under DPCO, 2013 and subject to fulfillment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturers/marketing companies. (f) The concerned manufacturers of above said formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of product in Form-III of Schedule-II of the DPCO, 2013 through IPDMS.10 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] Manufacturers, in case intending to discontinue above said formulations, shall furnish information to the NPPA, in respect of discontinuation of the production and/or import of above said formulation in Form-IV of Schedule- II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. (g) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955. (h) Consequent to the issue of retail price of the aforesaid formulations as specified in column (2) of the above mentioned table in this notification, the price order(s) if any, issued for concerned manufacturer/marketer prior to the above said date of notification, stand(s) superseded. [P N./177/45/2017/F /F. No. 8(45)/2017/D.P./NPPA-Div.-II] BALJIT SINGH, Assistant Director Uploaded by Dte. of Printing at Government of India Press, Ring Road, Mayapuri, New Delhi-110064 and Published by the Controller of Publications, Delhi-110054.